# Effectiveness of the hypotension prediction index in non-cardiac surgeries: a systematic review, meta-analysis and trial sequential analysis

## TL;DR

This study finds that the Hypotension Prediction Index reduces the severity and duration of low blood pressure during non-cardiac surgeries, without increasing adverse events.

## Contribution

The study provides a systematic review and meta-analysis confirming the effectiveness of HPI in reducing intraoperative hypotension in non-cardiac surgery patients.

## Key findings

- HPI significantly reduced the time-weighted average of mean arterial pressure below 65 mmHg.
- HPI decreased the duration of hypotension and the number of hypotensive episodes per patient.
- No significant differences were found in adverse events like AKI or phenylephrine use.

## Abstract

The efficacy of the Hypotension Prediction Index (HPI) for reducing Intraoperative Hypotension (IOH) among patients undergoing non-cardiac surgeries remains unclear. We aimed to perform a systematic review, meta-analysis, and trial sequential analysis to determine whether the HPI is effective for adult patients undergoing non-cardiac surgeries. This study was prospectively registered in the PROSPERO database (CRD42024571931).

PubMed, Embase, and Cochrane were systematically searched for Randomized Controlled Trials (RCTs) comparing HPI-guided therapy with standard care in non-cardiac surgeries. We computed Mean Difference (MD) and Risk Ratios (RR) for continuous and binary outcomes, respectively, with 95 % Confidence Intervals (95 % CI). Statistical analyses were performed using R Software, version 4.2.3.

We included 11 RCTs, comprising a total of 789 patients, of whom 395 (50.1 %) received HPI-guided management. HPI significantly reduced the Time-Weighted Average (TWA) of Mean Arterial Pressure (MAP) < 65 mmHg (MD = -0.23 mmHg.min-1; 95 % CI -0.35 to -0.10; p < 0.01) and the Area Under the Curve (AUC) of MAP < 65 mmHg (MD = -97.2 mmHg.min-1; 95 % CI -143.4 to -50.98; p < 0.01). HPI also decreased the duration of MAP < 65 mmHg (MD = -16.22 min; 95 % CI -25.87 to -6.57; p < 0.01) and the number of hypotensive episodes per patient (MD = -3.38; 95 % CI -5.38 to -1.37; p < 0.01). No significant differences were observed in the number of hypotensive events, phenylephrine use, or AKI incidence (p > 0.05).

In adult patients undergoing non-cardiac surgeries, HPI use was associated with a reduction in the duration and severity of IOH, with no significant difference for adverse events. Limitations include significant heterogeneity across studies, differences in HPI implementation, and lack of long-term outcome data.